Ballantyne Clinical Report

Key result of the Paper

• The Ballantyne report showed patients treated with Vytorin showed a greater reduction in cholesterol
• The study examined the efficacy of reduced cholesterol. Comparing Vytorin to other statin products
• Vytorin allowed patients to achieve cholesterol target. Success for patients not currently responding to other statins.

Why was the study done

• Primary target of the National Cholesterol Education program
• Testing the hypothesis that Vytorin provides greater reductions than other statins across dosage ranges

Why was the study done

• Primary target of the National Cholesterol Education program
• Testing the hypothesis that Vytorin provides greater reductions than other statins across dosage ranges

What it tells you

• 10 week study, 1900 patients. 57% reached cholesterol target in the trial
• Single dosage of 10/40mg. ages 18-79, average age 59
• 46% had cholesterol risk, 37% had multiple risks
• Vytorin was tolerated in the study and did not increase the risk of muscle or liver enzymes